Kovács A B
CHINOIN Pharmaceutical and Chemical Works Co. Ltd., Clinical Development Group, Budapest, Hungary.
Agents Actions. 1994 Mar;41(1-2):86-7. doi: 10.1007/BF01986400.
The efficacy of ipriflavone was investigated in a 1-year double-blind, placebo-controlled, parallel group clinical trial. Ninety-one postmenopausal women completed the study, 41 received ipriflavone and 50 placebo treatment. After six months the bone mineral density of the L2-L4 vertebral region increased in the ipriflavone-treated group (0.015 g/cm2), whereas it decreased in the placebo-treated group. The differences between the treatment groups were statistically significant. Our results support the efficacy of ipriflavone in the treatment of postmenopausal osteoporosis. Since the positive effect was more pronounced after 6 months, the possibility of an intermittent ipriflavone treatment might be taken into consideration in the future.
在一项为期1年的双盲、安慰剂对照、平行组临床试验中对异黄酮的疗效进行了研究。91名绝经后女性完成了该研究，41名接受异黄酮治疗，50名接受安慰剂治疗。6个月后，异黄酮治疗组L2-L4椎体区域的骨密度增加（0.015 g/cm²），而安慰剂治疗组的骨密度则下降。治疗组之间的差异具有统计学意义。我们的结果支持异黄酮治疗绝经后骨质疏松症的疗效。由于6个月后积极效果更为明显，未来可能会考虑间歇性异黄酮治疗的可能性。
